Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion | Stock Movers

On this episode of Stock Movers: Synaptics (SYNA) shares rise. Onsemi has agreed to buy Synaptics Inc. in an all-stock deal that values the company at about $6.2 billion. The transaction has a total enterprise value including debt of roughly $7 billion and is expected to close in mid-2027, subject to approvals. Lumentum (LITE) shares fall. U.S. optical communication stocks dropped. This comes as Semiconductor stocks are broadly lower. Acadia Pharma (ACAD) shares climb as much as 12%, the most intraday since May 2025, after the drugmaker said the European Medicines Agency’s CHMP issued a positive opinion for its drug to treat symptoms of Rett syndrome and recommended granting a marketing authorization. See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information. Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street. Check out more episodes of Stock Movers: https://www.youtube.com/playlist?list=PLe4PRejZgr0NxhJreY_kjMBdW8cvmNauU Visit us: https://www.bloomberg.com/podcasts Follow Bloomberg Podcasts on Twitter: https://twitter.com/podcasts Visit our other YouTube channels: Bloomberg Television: https://www.youtube.com/@markets Bloomberg Originals: https://www.youtube.com/bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake For coverage on news, markets and more: http://www.bloomberg.com/video #Stocks #Markets #Finance #Investing #Podcast #Bloomberg Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion